NEDD8-activating enzyme inhibition induces cell cycle arrest and anaphase catastrophe in malignant T-cells.
T-cell lymphoma
anaphase catastrophe
chromosomal instability
pevonedistat
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
28 Sep 2021
28 Sep 2021
Historique:
received:
26
06
2021
accepted:
18
08
2021
entrez:
6
10
2021
pubmed:
7
10
2021
medline:
7
10
2021
Statut:
epublish
Résumé
Peripheral T-cell lymphoma (PTCL) is characterized by poor outcomes. We and others have shown that targeting the NEDD8-activating enzyme (NAE) with an investigational inhibitor pevonedistat deregulates cell cycle and mitosis in lymphoma and leukemia. Here, we report that PTCL is characterized by increased rate of chromosomal instability. NAE inhibition promotes cell cycle arrest and induces multipolar anaphases in T-cell lymphoma cell lines, resulting in apoptosis, also observed in primary malignant PTCL cells treated with pevonedistat. We identified p27
Identifiants
pubmed: 34611480
doi: 10.18632/oncotarget.28063
pii: 28063
pmc: PMC8487718
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2068-2074Informations de copyright
Copyright: © 2021 Kittai et al.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST A.S.K. consults for Bristol Meyers Squibb. A.V.D. received consulting fees from Abbvie, AstraZeneca, BeiGene, Genentech, Pharmacyclics and TG Therapeutics and has ongoing research funding from AstraZeneca, Bayer Oncology, Bristol Meyers Squibb, Genentech, MEI Pharma, SecuraBio, TG Therapeutics and Takeda Oncology.
Références
Haematologica. 2018 Jul;103(7):1191-1197
pubmed: 29599200
Curr Protein Pept Sci. 2004 Jun;5(3):177-84
pubmed: 15180522
Cancer Cell. 2005 Jun;7(6):591-8
pubmed: 15950907
Leukemia. 2021 Jan;35(1):156-168
pubmed: 32203139
Blood. 2016 Mar 3;127(9):1128-37
pubmed: 26675347
Mol Cancer Ther. 2018 Apr;17(4):724-731
pubmed: 29559545
Cancer Res. 2010 Dec 15;70(24):10310-20
pubmed: 21159650
Blood. 2010 Sep 2;116(9):1515-23
pubmed: 20525923
EJHaem. 2020 Jul;1(1):122-132
pubmed: 33073261
Clin Cancer Res. 2011 Dec 15;17(24):7704-11
pubmed: 22184286
Cancer Res. 2015 May 15;75(10):2029-38
pubmed: 25808870
Leukemia. 2019 Dec;33(12):2867-2883
pubmed: 31092896
Cell Death Dis. 2015 Jul 09;6:e1807
pubmed: 26158513
Science. 2014 Jan 3;343(6166):84-87
pubmed: 24336571
Mol Cancer Ther. 2016 Nov;15(11):2758-2766
pubmed: 27550941
Oncogene. 2013 Mar 14;32(11):1441-51
pubmed: 22641220
Cancer Res. 2011 Apr 15;71(8):3042-51
pubmed: 21487042
Blood. 2018 May 24;131(21):2320-2330
pubmed: 29666117
Cancer Lett. 2017 Sep 10;403:354-365
pubmed: 28687353